Compass Therapeutics (NASDAQ:CMPX) Stock Rating Upgraded by Wall Street Zen

Compass Therapeutics (NASDAQ:CMPX) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Monday.

Other research analysts also recently issued reports about the company. D. Boral Capital restated a “buy” rating and issued a $30.00 price target on shares of Compass Therapeutics in a research note on Tuesday, January 6th. Leerink Partners raised shares of Compass Therapeutics to a “strong-buy” rating in a report on Wednesday, November 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compass Therapeutics in a research note on Wednesday, January 21st. William Blair assumed coverage on shares of Compass Therapeutics in a report on Monday, January 5th. They issued an “outperform” rating on the stock. Finally, Craig Hallum initiated coverage on shares of Compass Therapeutics in a research note on Friday, February 13th. They issued a “buy” rating and a $15.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $13.25.

Compass Therapeutics Stock Up 1.8%

Shares of Compass Therapeutics stock opened at $6.39 on Monday. The company has a market capitalization of $1.14 billion, a price-to-earnings ratio of -14.20 and a beta of 1.46. The stock’s 50-day simple moving average is $5.71 and its 200-day simple moving average is $4.55. Compass Therapeutics has a 52 week low of $1.33 and a 52 week high of $6.88.

Hedge Funds Weigh In On Compass Therapeutics

Several large investors have recently modified their holdings of CMPX. Suvretta Capital Management LLC boosted its stake in shares of Compass Therapeutics by 97.2% during the third quarter. Suvretta Capital Management LLC now owns 14,101,159 shares of the company’s stock valued at $49,354,000 after purchasing an additional 6,951,666 shares during the period. Vivo Capital LLC lifted its holdings in Compass Therapeutics by 57.9% during the 3rd quarter. Vivo Capital LLC now owns 9,545,466 shares of the company’s stock valued at $33,409,000 after buying an additional 3,502,000 shares in the last quarter. Balyasny Asset Management L.P. purchased a new stake in Compass Therapeutics in the 3rd quarter valued at about $9,892,000. Braidwell LP bought a new position in Compass Therapeutics in the 4th quarter worth about $14,965,000. Finally, Millennium Management LLC grew its stake in Compass Therapeutics by 280.4% in the 3rd quarter. Millennium Management LLC now owns 3,237,572 shares of the company’s stock worth $11,332,000 after acquiring an additional 2,386,367 shares in the last quarter. Institutional investors own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.